On July 29th, 2021, Friends of Cancer Research (Friends) hosted a virtual meeting revolving around the recently released 21st Century Cures 2.0 discussion draft. It featured a discussion panel of Representative Diana DeGette (D-CO), Representative Fred Upton (R-MI), Dr. Ned Sharpless, Director of the National Cancer Institute, and Dr. Richard Pazdur, Director of the Oncology Center of Excellence at the U.S. Food and Drug Administration (FDA).

Creating a New Cancer Research Paradigm by Broadening Eligibility Criteria

The American Society of Clinical Oncology (ASCO, a professional society for cancer clinicians and researchers) and Friends of Cancer Research (Friends, a cancer advocacy organization focused on advancing science, policy, and regulation) have been collaborating to promote broader, more inclusive cancer clinical trial eligibility crite

Creating a New Cancer Research Paradigm by Broadening Eligibility Criteria

The American Society of Clinical Oncology (ASCO, a professional society for cancer clinicians and researchers) and Friends of Cancer Research (Friends, a cancer advocacy organization focused on advancing science, policy, and regulation) have been collaborating to promote broader, more inclusive cancer clinical trial eligibility criteria since 2016.

On February 11, 2021, Friends of Cancer Research (Friends) hosted a virtual meeting highlighting and discussing the progress, challenges, and future of immunotherapies and cell therapies. Ellen Sigal, Chairperson & Founder of Friends, gave opening remarks and introduced keynote speaker Ned Sharpless, Director of the National Cancer Institute (NCI). Sharpless spoke about the progress made to date in immuno-oncology (IO), ongoing efforts to advance the field at NCI, as well as regulatory challenges for IO and other novel therapies.

I was 18 when my life was turned upside down by cancer. My mother was diagnosed with a highly aggressive malignancy after a colonoscopy due to a flair-up of Crohn’s disease. She spent the next two months in the hospital after the surgery to remove the malignancy left her near death with adhesions, requiring a second, corrective surgery, and a long recovery.

 

To this day, I don’t really understand how my family held it together and, even though my mom has been cancer free for more than 10 years now, that experience has impacted everything that I have done since.

As part of Pfizer's ongoing "Pfizer Partnerships" video series, Friends of Cancer Research Founder and Chairperson Ellen Sigal discussed the structure and promise of the Lung-MAP clinical trial. "Lung-MAP is about collaboration of all sectors working towards a common goal, and that's to help patients with squamous cell lung cancer," said Dr. Sigal. "It's about working together on a way to find faster, better answers."

Subscribe to NCI